Filing Details

Accession Number:
0001209191-21-038854
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-08 15:16:49
Reporting Period:
2021-06-07
Accepted Time:
2021-06-08 15:16:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
59478 Eli Lilly & Co LLY Pharmaceutical Preparations (2834) 350470950
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
316011 Lilly Endowment Inc 2801 North Meridian Street
Indianapolis IN 46208-0068
No No Yes No
Transaction Summary
Sold: 230,000 shares Avg. Price: $224.72 Total Value: $51,685,007.87
Number of Shares After Transactions: 109,872,100 shares
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-06-07 11,069 $219.09 110,091,031 No 4 S Direct
Common Stock Disposition 2021-06-07 5,625 $220.36 110,085,406 No 4 S Direct
Common Stock Disposition 2021-06-07 14,621 $221.12 110,070,785 No 4 S Direct
Common Stock Disposition 2021-06-07 29,489 $222.40 110,041,296 No 4 S Direct
Common Stock Disposition 2021-06-07 46,716 $223.17 109,994,580 No 4 S Direct
Common Stock Disposition 2021-06-07 33,646 $224.27 109,960,934 No 4 S Direct
Common Stock Disposition 2021-06-07 21,187 $225.17 109,939,747 No 4 S Direct
Common Stock Disposition 2021-06-07 10,627 $226.33 109,929,120 No 4 S Direct
Common Stock Disposition 2021-06-07 10,010 $227.27 109,919,110 No 4 S Direct
Common Stock Disposition 2021-06-07 6,700 $228.38 109,912,410 No 4 S Direct
Common Stock Disposition 2021-06-07 17,321 $229.46 109,895,089 No 4 S Direct
Common Stock Disposition 2021-06-07 15,125 $230.14 109,879,964 No 4 S Direct
Common Stock Disposition 2021-06-07 6,164 $231.36 109,873,800 No 4 S Direct
Common Stock Disposition 2021-06-07 1,100 $232.03 109,872,700 No 4 S Direct
Common Stock Disposition 2021-06-07 600 $233.23 109,872,100 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.60 to $219.41, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), and (15) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.6005 to $220.60, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.61 to $221.54, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.7003 to $222.70, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $222.73 to $223.7293, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $223.743 to $224.74, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $224.7442 to $225.73, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $225.7467 to $226.74, inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $226.79 to $227.777, inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $227.83 to $228.8247, inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.83 to $229.82, inclusive.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.85 to $230.79, inclusive.
  13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $230.87 to $231.86, inclusive.
  14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $231.89 to $232.88, inclusive.
  15. The price reported in Column 4 is a weighted average price. These shares were sold at prices of $232.91 and $233.29.